About this event
Can doctors predict in advance whether a treatment will work for an individual patient? Or whether it might cause serious side effects? Techniques that harness the power of DNA technology and point-of-care prescribing decision support are now making this possible in the field of pharmacogenomics.
Join us as Dr. Peter O’Donnell discusses these advancements, including several examples of current clinical settings and models that utilize genomic information to tailor prescribing. Dr. O’Donnell will argue that, in the current age of precision medicine, the pertinent question might instead be: why don’t more doctors use such information already?
Who can attend
Registration is limited to ISMIE and SEMPIC policyholders and their employed staff.
Learning objectives
At the conclusion of this learning activity, participants will be able to:
- Summarize current evidence for how genomic information can inform the prescribing of commonly used drugs
- Illustrate current applications of the implementation of genomic information in clinical settings to tailor prescribing
- Identify potential barriers to more widespread use of genomics to inform prescribing
About the presenter
Peter H. O’Donnell, MD, is a physician-scientist with advanced training in clinical pharmacology and a practicing medical oncologist specializing in the treatment of genitourinary malignancies, specifically bladder cancer. His research focuses on elucidation of germline genetic markers that predict medication response (pharmacogenomics).
Dr. O’Donnell’s work explores facilitating and understanding the delivery and adoption of genomic information at the point of care to inform prescribing. He is especially interested in assessing whether the critical mass of clinically actionable germline pharmacogenomic information can be utilized in practice if barriers to implementation can be overcome. He was PI of “The 1200 Patients Project”, an NIH-funded clinical research study that examined how preemptive pharmacogenomic test results could be incorporated into treatment decisions. Dr. O’Donnell was also Translational Project Lead for a multi-institutional cooperative agreement (NIH U54) examining pharmacogenomic implementation questions for hospitalized minority patients. He additionally currently leads a large institutional project examining pharmacogenomic utilization during perioperative/critical care and pain management through another NIH-funded study (R01), and is also exploring pharmacogenomic utilization to reduce adverse events among oncology patients.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Illinois State Medical Society and ISMIE Mutual Insurance Company. The Illinois State Medical Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Illinois State Medical Society designates this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure
There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.
ISMIE Risk Management
Our Passion Protects YoursISMIE Mutual provides superior insurance services to medical practices and providers, delivering quality, value and protection to policyholders everywhere.
